Loading...
•
Jun 30, 2023
OptimizeRx Q2 2023 Earnings Report
OptimizeRx's Q2 2023 results fell below internal expectations due to revenue shortfall in non-core business lines and longer MLR reviews.
Key Takeaways
OptimizeRx reported Q2 2023 financial results with a total revenue of $13.8 million. The company experienced a GAAP net loss per share of $(0.24) and a non-GAAP net loss per share of $(0.01). The RWD.AI-enabled portion of the core business saw 186% year-over-year growth during the first half of 2023.
Q2 results fell below internal expectations due to revenue shortfall in non-core business lines.
Longer than expected MLR reviews pushed revenue into the second half of the year.
Macro headwinds are expected to persist through 2023.
RWD.AI-enabled healthcare technology platform experienced 186% year-over-year growth.
Forward Guidance
OptimizeRx is updating its full year financial outlook for 2023, expecting revenues in the mid-50 to low-60 million dollar range with a gross margin rate between 55% and 59%.
Historical Earnings Impact
Analyze how earnings announcements historically affect stock price performance
Avg. Return Before/After Earnings
Loading earnings performance data...
Loading earnings reaction data...